{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-021348","form_type":"8-K","ticker":"EQ","cik":"0001746466","company_name":"Equillium, Inc.","filed_at":"2025-02-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.697308+00:00","generated_at":"2026-05-27T01:44:31.380697+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Equillium reports itolizumab Phase 2 UC topline: 23.3% clinical remission vs 10% placebo","bullets":["Primary endpoint: 23.3% clinical remission at week 12 for itolizumab vs 20.0% adalimumab, 10.0% placebo.","Secondary: 63.3% clinical response (itolizumab) vs 60.0% adalimumab, 46.7% placebo; endoscopic remission 16.7% each itolizumab/adalimumab vs 6.7% placebo.","Baseline imbalance: 23% of itolizumab arm had severe disease (Mayo=11) vs 0% placebo/adalimumab; 66% left-sided colitis vs 30%/43%.","Itolizumab was generally well tolerated with no new safety signal; 90 patients randomized 1:1:1 in India."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-021348","json":"https://secwatch.observer/filing/0001193125-25-021348.json","markdown":"https://secwatch.observer/filing/0001193125-25-021348.md","text":"https://secwatch.observer/filing/0001193125-25-021348.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1746466/000119312525021348/0001193125-25-021348-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1746466/000119312525021348/d898732d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T01:44:31.380697+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}